22:59 , Jul 8, 2019 |  BC Extra  |  Company News

July 8 Company Quick Takes: Merck, Skyhawk in discovery deal; plus MorphoSys, BioMarin, Roche-Spark and Hanmi

Skyhawk, Merck in neurology, cancer deal  Skyhawk Therapeutics Inc. (Waltham, Mass.) and Merck & Co. Inc. (NYSE:MRK) parterned to discover, develop and commercialize small molecules capable of modulating RNA splicing discovered using Skyhawk’s SkySTAR platform...
20:14 , Dec 21, 2018 |  BC Week In Review  |  Financial News

Shanghai Henlius up for Hong Kong IPO

Biosimilars company Shanghai Henlius Biotech Inc. (Shanghai, China) proposed on Dec. 14 to list on the Hong Kong stock exchange. Shanghai Henlius' lead compound is HLX01, a biosimilar of cancer and autoimmune drug MabThera rituximab...
00:06 , Dec 15, 2018 |  BC Extra  |  Financial News

Shanghai Henlius up for Hong Kong IPO

Biosimilars company Shanghai Henlius Biotech Inc. (Shanghai, China) proposed on Friday to list on the Hong Kong stock exchange. Shanghai Henlius' lead compound is HLX01, a biosimilar of cancer and autoimmune drug MabThera rituximab from...
23:58 , Apr 19, 2018 |  BC Innovations  |  Product R&D

Automation navigation

Last year’s approvals of the first two CAR T therapies have prompted the field to get serious about industrializing manufacturing of the cells to improve reproducibility and lower costs. While stakeholders agree that automation will...
19:30 , Nov 3, 2017 |  BC Week In Review  |  Clinical News

Probiodrug planning Phase IIb trials of PQ912 for early AD

Next year, Probiodrug AG (Euronext:PBD) plans to start a European Phase IIb trial of glutaminyl cyclase (QC) inhibitor PQ912 to treat early Alzheimer’s disease. The trial will evaluate safety and efficacy of the optimal dose...
19:21 , Jul 31, 2017 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Alzheimer's disease (AD) In vitro , cell culture and mouse studies identified a diphenyl-imidazole-based QC inhibitor that could help treat AD. Chemical synthesis and in vitro testing of diphenyl-imidazole analogs yielded a compound that...
21:47 , Jul 21, 2017 |  BioCentury  |  Product Development

Surrogate start

Phase II results for Probiodrug AG ’s Alzheimer’s disease candidate point to potential surrogate markers for improvements in cognition that one day could be used in early development to handicap the likelihood of success in...
22:53 , Jun 29, 2017 |  BC Innovations  |  Strategy

Lilly goes with the flow

In line with FDA ’s push for companies to shift from batch processing to continuous manufacturing, Eli Lilly and Co. has published details of the first CGMP process for an API. The system shrinks a...
21:32 , Jun 16, 2017 |  BC Week In Review  |  Clinical News

Probiodrug reports Phase IIa data for glutaminyl cyclase inhibitor in early AD

Probiodrug AG (Euronext:PBD) reported data from the Phase IIa SAPHIR trial in 120 patients with early Alzheimer's disease (AD) showing that there was no significant difference between patients who received twice-daily 800 mg oral PQ912...
02:31 , Mar 4, 2017 |  BioCentury  |  Product Development

Diagnosing AD trials

A battery of expensive late-stage failures has made it obvious to Alzheimer’s disease companies that more and better diagnostics will be essential to get new disease-modifying therapies to patients. But so far, the approaches being...